155 related articles for article (PubMed ID: 26553781)
1. Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.
Zeidner JF; Karp JE; Blackford AL; Foster MC; Dees EC; Smith G; Ivy SP; Harris P
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26553781
[TBL] [Abstract][Full Text] [Related]
2. Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.
Østgård LS; Nørgaard M; Sengeløv H; Medeiros BC; Kjeldsen L; Overgaard UM; Severinsen MT; Marcher CW; Jensen MK; Nørgaard JM
Oncotarget; 2016 Nov; 7(44):72044-72056. PubMed ID: 27732947
[TBL] [Abstract][Full Text] [Related]
3. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.
Ho G; Wun T; Muffly L; Li Q; Brunson A; Rosenberg AS; Jonas BA; Keegan THM
Cancer; 2018 May; 124(9):1938-1945. PubMed ID: 29451695
[TBL] [Abstract][Full Text] [Related]
4. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
Chihara D; Huang EP; Finnigan SR; Cordes LM; Skorupan N; Fukuda Y; Rubinstein LV; Ivy SP; Doroshow JH; Nastoupil LJ; Flowers CR; Takebe N
J Clin Oncol; 2022 Jun; 40(17):1949-1957. PubMed ID: 35263120
[TBL] [Abstract][Full Text] [Related]
5. Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina.
Freeman AT; Meyer AM; Smitherman AB; Zhou L; Basch EM; Shea TC; Wood WA
Cancer; 2016 Oct; 122(19):3041-50. PubMed ID: 27351768
[TBL] [Abstract][Full Text] [Related]
6. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis.
Percival ME; Tao L; Medeiros BC; Clarke CA
Cancer; 2015 Jun; 121(12):2004-12. PubMed ID: 25739348
[TBL] [Abstract][Full Text] [Related]
7. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
9. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
Lynce F; Blackburn MJ; Cai L; Wang H; Rubinstein L; Harris P; Isaacs C; Pohlmann PR
Breast Cancer Res Treat; 2018 Feb; 168(1):35-41. PubMed ID: 29119354
[TBL] [Abstract][Full Text] [Related]
11. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
Badar T; Shetty A; Bueso-Ramos C; Cortes J; Konopleva M; Borthakur G; Pierce S; Huang X; Chen HC; Kadia T; Daver N; Dinardo C; O'Brien S; Garcia-Manero G; Kantarjian H; Ravandi F
Am J Hematol; 2015 Sep; 90(9):769-73. PubMed ID: 26017166
[TBL] [Abstract][Full Text] [Related]
13. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
14. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Badar T; Kantarjian HM; Nogueras-Gonzalez GM; Borthakur G; Garcia Manero G; Andreeff M; Konopleva M; Kadia TM; Daver N; Wierda WG; Luthra R; Patel K; Oran B; Champlin R; Ravandi F; Cortes JE
Am J Hematol; 2015 Nov; 90(11):1065-70. PubMed ID: 26299958
[TBL] [Abstract][Full Text] [Related]
15. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK; Russell NH; Kell J; Dennis M; Milligan D; Paolini S; Yin J; Culligan D; Johnston P; Murphy J; McMullin MF; Hunter A; Das-Gupta E; Clark R; Carr R; Hills RK
J Clin Oncol; 2010 May; 28(14):2389-95. PubMed ID: 20385984
[TBL] [Abstract][Full Text] [Related]
16. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
17. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton CB; Ravandi F
Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
[TBL] [Abstract][Full Text] [Related]
18. [Treatment conditioning variables in elderly patients with acute myeloid leukemia. An institutional experience].
Giménez Conca AD; Arbelbide JA; Schutz N; Otero V; Fantl D; Ferreyro B
Medicina (B Aires); 2016; 76(2):81-8. PubMed ID: 27135845
[TBL] [Abstract][Full Text] [Related]
19. CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
Brunetti C; Anelli L; Zagaria A; Specchia G; Albano F
Expert Rev Hematol; 2017 Oct; 10(10):853-862. PubMed ID: 28814164
[TBL] [Abstract][Full Text] [Related]
20. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ
J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]